---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-24-000101"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2024-12-23T23:59:59+00:00"
generated_at: "2026-05-28T23:37:21.882827+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Salarius stockholders re-elect directors, approve say-on-pay, ratify auditor at annual meeting

## Summary
- Two Class III directors re-elected: Tess Burleson (141,974 for) and Paul Lammers (145,485 for).
- Non-binding advisory vote on named executive officer compensation approved (135,949 for, 18,637 against).
- Ratification of Ernst & Young LLP as independent auditor for FY 2024 approved (496,239 for, 59,576 against).
- Quorum of 39.7% (572,540 of 1,441,157 shares) present at December 20, 2024 meeting.

## SEC filing metadata
- accession: 0001615219-24-000101
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2024-12-23T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521924000101/0001615219-24-000101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521924000101/flks-20241220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-24-000101
- JSON: https://secwatch.observer/filing/0001615219-24-000101.json
- Plain text: https://secwatch.observer/filing/0001615219-24-000101.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.